Latest News

Vanessa Almendro-Navarro, PhD, MBA, outlined what she hopes to accomplish in her new role as chief commercialization officer at City of Hope.

A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.

The new living guideline contains updated recommendations for biomarker testing and therapeutic strategies based on factors like PD-L1 expression status.

Fumiko Chino, MD, discussed the nuances of patient-centered care, addressing financial toxicity, AI bias in oncology, and survivorship.

Cytokines such as IL-17B, TNF-α, and IL-6 are essential in driving neuroendocrine differentiation and “reprogramming” healthy tissue.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for tirabrutinib in this relapsed/refractory group.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Patient characteristics such as female sex and receipt of pylorus-preserving gastrectomy were protective of gallstone disease risk in those who had gastric cancer.

Findings presented at the 2026 Tandem Meetings, showed an accelerated immune constitution of donor derived CD4-positive T cells was observed with TRX103.

Data from the EXCALIBER-RRMM trial support the application for iberdomide plus standard therapy in this relapsed/refractory multiple myeloma population.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Monthly dosing of subcutaneous amivantamab may confer consistent outcomes with the previously approved biweekly dosing schedule in EGFR-mutant NSCLC.

According to Emese Zsiros, MD, PhD, FACOG, the pembrolizumab regimen yields favorable responses and survival in this PROC population.

Further follow-up is necessary to see if AZD0120 may be preferentially used as a treatment for patients with relapsed/refractory multiple myeloma.

Neoadjuvant therapy improves survival for patients with upfront resectable pancreatic cancer and minor PMV abutment vs an upfront surgical approach.

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Although many clinical trials end due to strategic reasons, easing inclusion criteria and reducing potential operational failure may mitigate terminations.

J. Isabelle Choi, MD, discussed proton and photon therapy for locoregional recurrences, emphasizing advanced IMRT/VMAT techniques and CTV delineation.

Investigators will share detailed results from the phase 3 LIBRETTO-432 trial assessing selpercatinib in NSCLC at a future medical meeting.

Since 2003, breast cancer has been one of the black box warnings associated with hormone replacement therapy for women experiencing menopause.

Researchers and clinicians share key updates in leukemia, lymphoma, and myelodysplastic syndrome that they presented at the 2026 Tandem Meetings.

Diane Simeone, MD, detailed how the PRECEDE Consortium utilizes standardized data sharing and high-risk screening to identify stage I pancreatic cancer.

Julie M. Vose, MD, MBA, details insights from the Mantle Cell Lymphoma Scientific Consortium and Workshop, focusing on global clinical trial collaboration and sequencing BTK/BCL-2 inhibitors.

In a presentation at the 2026 ACRO Summit, Pranshu Mohindra, MD, reviewed the treatment planning process for hypofractionated radiation in lung cancer.

This section aims to enhance provider empathy, mitigate burnout, and center the patient’s lived experience within the rigorous framework of medical science.

Irtiza N. Sheikh, DO, hopes liso-cel accessibility increases in non-clinical trial settings and is considered for use earlier in the LBCL treatment course.

Diane Simeone, MD, highlights the necessity of a collaborative approach to pancreatic cancer screening, similar to trends across multiple disease states.

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.